Medical device and MedTech insights, news, tips and more

Zimmer Agrees to Buy LDR for $1 Billion

June 8, 2016



Zimmer Biomet Holdings Inc (ZBH.N) agreed to buy fellow medical device maker LDR Holding Corp (LDRH.O) for about $1 billion deal to expand in the market for treating spine disorders.

The $37 per share offer represents a premium of about 64 percent to LDR’s Monday close.

LDR’s shares were trading at $36.94 on Tuesday, on track for their best day ever. They briefly climbed above the offer price to $37.09 in early trading.

Zimmer’s stock was down 2.6 percent at $118.28.

The LDR deal follows Medtronic Plc (MDT.N) in May picking up a stake in Israeli robotics company Mazor Robotics Ltd (MZOR.TA) (MZOR.O) and agreeing to use Mazor’s robotic guidance systems that assist surgeons in spine and brain operations.

The Medtronic/Mazor deal in May and the Zimmer announcement suggest consolidation may finally be taking shape in the spine market, Wells Fargo analysts wrote on Tuesday.

Founded in France in 2000, LDR develops surgical technology for spine disorders.

The company’s biggest product is Mobi-C CDR, the first and only U.S. Food and Drug Administration approved device to treat both one- and two-level adjacent damaged cervical discs.

Cervical disc replacement (CDR) represents the fastest-growing segment within the $10-billion spine industry, the companies said.

However, the Wells Fargo analysts said they had been cautious on the near-term outlook for Mobi-C as the cervical disc market has not grown as quickly as expected, largely due to reimbursement issues.

Also, competition is likely to rise, with Medtronic’s device, Prestige LP, expected to get approval for the same indication as Mobi-C this year, the analysts said.

Read More – Source: Zimmer props up spine device business with $1 billion LDR buy

(Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.